ELYM Stock Price, Eliem Therapeutics, Inc. Quote, Chart

Market Summary

USD8.24+0.06

Delayed

0.73%

ELYM Stock Price

View Fullscreen

ELYM RSI Chart

ELYM Valuation

Market Cap

239.7M

Price/Earnings (Trailing)

-16.5

Price/Sales (Trailing)

47.36

Price/Free Cashflow

-33.1

ELYM Price/Sales (Trailing)

ELYM Profitability

Return on Equity

-13.65%

Return on Assets

-13.29%

Free Cashflow Yield

-3.02%

ELYM Fundamentals

ELYM Revenue

Revenue (TTM)

5.1M

Rev. Growth (Yr)

49%

Rev. Growth (Qtr)

-0.59%

ELYM Earnings

Earnings (TTM)

-14.5M

Earnings Growth (Yr)

92.39%

Earnings Growth (Qtr)

53.39%

Breaking Down ELYM Revenue

Last 7 days

-2.6%

Last 30 days

86%

Last 90 days

215.7%

Trailing 12 Months

174.7%

How does ELYM drawdown profile look like?

ELYM Financial Health

Current Ratio

37.02

ELYM Investor Care

Shares Dilution (1Y)

7.77%

Diluted EPS (TTM)

-0.53

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	5.1M	0	0	0
2023	2.2M	3.0M	3.8M	4.6M
2022	0	0	0	1.4M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Eliem Therapeutics, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 05, 2024	morisset valerie	acquired	3.5694	0.0002	17,847	evp, r&d and cso
Sep 20, 2023	morisset valerie	acquired	13.9214	0.000671623	20,728	evp, r&d and cso
Mar 10, 2023	morisset valerie	acquired	522	0.0016519	316,410	evp, r&d and cso
Aug 12, 2021	ra capital management, l.p.	bought	40,000,000	12.5	3,200,000	-
Aug 12, 2021	ra capital management, l.p.	acquired	-	-	6,867,520	-
Aug 12, 2021	ai eti llc	bought	10,000,000	12.5	800,000	-
Aug 12, 2021	ai eti llc	acquired	-	-	4,209,400	-

Which funds bought or sold ELYM recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	Driehaus Capital Management LLC	unchanged	-	32,467	2,224,000	0.02%
May 15, 2024	STATE STREET CORP	unchanged	-	1,302	59,458	-%
May 15, 2024	Tudor Investment Corp Et Al	reduced	-0.08	1,114	80,737	-%
May 15, 2024	MORGAN STANLEY	unchanged	-	69.00	4,683	-%
May 15, 2024	BANK OF AMERICA CORP /DE/	sold off	-100	-8.00	-	-%
May 15, 2024	Atom Investors LP	unchanged	-	3,131	214,476	0.03%
May 15, 2024	Tower Research Capital LLC (TRC)	added	4.37	552	9,880	-%
May 15, 2024	RA CAPITAL MANAGEMENT, L.P.	unchanged	-	526,034	36,033,300	0.46%
May 15, 2024	MILLENNIUM MANAGEMENT LLC	added	9.14	5,716	55,090	-%
May 15, 2024	BRIDGEWAY CAPITAL MANAGEMENT, LLC	unchanged	-	3,313	151,311	-%

Are Funds Buying or Selling ELYM?

Are funds buying ELYM calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ELYM

No. of Funds

Unveiling Eliem Therapeutics, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
May 07, 2024	affinity asset advisors, llc	6.02%	1,670,000	SC 13G
Apr 12, 2024	ra capital management, l.p.	47.5%	13,189,736	SC 13D/A
Mar 18, 2024	ra capital management, l.p.	47.5%	13,179,181	SC 13D/A
Feb 07, 2024	bml investment partners, l.p.	7.9%	2,180,000	SC 13G/A
Nov 17, 2023	ra capital management, l.p.	47.7%	13,176,403	SC 13D/A
Nov 13, 2023	ai eti llc	18.5%	5,009,400	SC 13D/A
Apr 10, 2023	ra capital management, l.p.	48.8%	13,163,071	SC 13D/A
Mar 08, 2023	intermediate capital group plc	7.5%	2,002,563	SC 13G/A
Feb 14, 2023	samlyn capital, llc	0%	0	SC 13G/A
Feb 08, 2023	bml investment partners, l.p.	6.9%	1,825,134	SC 13G/A

Recent SEC filings of Eliem Therapeutics, Inc.

View All Filings

Date Filed	Form Type	Document
May 17, 2024	SC 13D/A	13D - Major Acquisition
May 17, 2024	SC 13D/A	13D - Major Acquisition
May 17, 2024	PREM14A	PREM14A
May 15, 2024	10-Q	Quarterly Report
May 07, 2024	SC 13G	Major Ownership Report
Apr 29, 2024	10-K/A	Annual Report
Apr 12, 2024	SC 13D/A	13D - Major Acquisition
Apr 11, 2024	DEFA14A	DEFA14A
Apr 11, 2024	8-K	Current Report
Apr 08, 2024	4	Insider Trading

Peers (Alternatives to Eliem Therapeutics, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	233.93%	75.07%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Eliem Therapeutics, Inc. News

Latest updates

Eliem Therapeutics, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)								(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2
Revenue	-0.6%	1,341	1,349	1,261	1,110	900	642	383	147
Operating Expenses	-41.3%	3,005	5,122	5,001	6,714	23,438	9,554	8,748	13,701
S&GA Expenses	-100.0%	-	1,995	2,125	3,026	17,718	4,627	4,490	4,932
R&D Expenses	-65.1%	1,091	3,127	2,876	3,688	5,720	4,927	4,258	8,769
Income Taxes	-	-	-	-	-	-	-	-	-
Net Income	53.4%	-1,697	-3,641	-3,968	-5,220	-22,290	-7,762	-9,682	-14,596
Net Income Margin	62.2%	-2.87*	-7.60*	-10.30*	-15.00*	-24.85*	-32.90*	-	-
Free Cashflow	-92.1%	-1,819	-947	3,490	-7,965	-15,177	-8,449	-4,175	-13,966

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet													(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2020Q4
Assets	-1.0%	109	110	113	116	122	135	141	150	162	173	182	108	25.00
Current Assets	-0.9%	109	110	112	114	120	134	133	133	133	148	159	105	22.00
Cash Equivalents	12.8%	105	93.00	57.00	25.00	34.00	44.00	36.00	33.00	32.00	47.00	63.00	99.00	20.00
Liabilities	2.8%	3.00	3.00	3.00	4.00	5.00	6.00	6.00	8.00	7.00	6.00	6.00	6.00	3.00
Current Liabilities	4.1%	3.00	3.00	3.00	4.00	5.00	6.00	6.00	8.00	7.00	6.00	6.00	6.00	3.00
Shareholder's Equity	-1.1%	106	108	110	113	117	129	134	142	155	167	177	-	-
Retained Earnings	-1.1%	-157	-155	-152	-148	-143	-120	-113	-103	-88.82	-75.62	-65.07	-55.46	-28.14
Additional Paid-In Capital	0.2%	264	264	262	261	260	250	248	246	244	243	242	5.00	3.00
Shares Outstanding	0.1%	28.00	28.00	27.00	27.00	27.00	27.00	26.00	26.00	26.00	27.00	8.00	3.00	-
Float	-	-	-	-	13.00	-	-	-	14.00	-	-	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2
Cashflow From Operations	-92.1%	-1,819	-947	3,490	-7,965	-15,177	-8,449	-4,175	-13,966	-10,779	-7,884	-12,967	-8,481	-6,740	-	-	-
Share Based Compensation	-61.3%	465	1,202	656	777	10,171	1,895	1,783	1,772	1,541	1,154	1,236	1,050	297	-	-	-
Cashflow From Investing	-62.6%	13,751	36,748	28,037	-1,601	5,797	14,278	8,509	15,688	-4,035	-8,051	-106,919	-	-	-	-	-
Cashflow From Financing	-94.8%	15.00	288	528	24.00	1.00	-	-	-	-	38.00	83,144	59,967	34,083	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

ELYM Income Statement

2024-03-31

Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating expenses:
Research and development	$ 1,091	$ 5,720
General and administrative	1,914	17,718
Total operating expenses	3,005	23,438
Loss from operations	(3,005)	(23,438)
Other income (expense):
Foreign currency gain (loss)	(33)	248
Interest Income, Net	1,341	900
Total other income (expense)	1,308	1,148
Net loss	$ (1,697)	$ (22,290)
Net loss per share, basic	$ (0.06)	$ (0.84)
Net loss per share, diluted	$ (0.06)	$ (0.84)
Weighted-average number of shares outstanding used to compute net loss per share, basic	27,638,528	26,492,438
Weighted-average number of shares outstanding used to compute net loss per share, diluted	27,638,528	26,492,438
Comprehensive loss:
Net Income (Loss)	$ (1,697)	$ (22,290)
Other comprehensive loss
Unrealized gain (loss) on investments, net of tax of $0	2	263
Comprehensive loss	$ (1,695)	$ (22,027)

ELYM Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 105,031	$ 93,112
Short-term marketable securities	0	13,686
Prepaid expenses and other current assets	4,192	3,457
Total current assets	109,223	110,255
Operating lease right-of-use assets	111	199
Other long-term assets	0	15
Total assets	109,334	110,469
Current liabilities:
Accounts payable	85	66
Accrued expenses and other current liabilities	2,640	2,433
Operating lease liabilities	225	334
Total current liabilities	2,950	2,833
Operating lease liabilities, net of current portion	0	15
Other long-term liabilities	0	22
Total liabilities	2,950	2,870
Commitments and contingencies (Note 4)
Stockholders' equity
Common stock, $0.0001 par value per share, 250,000,000 shares authorized; 27,723,824 and 27,699,446 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively	3	3
Additional paid-in capital	264,057	263,577
Accumulated other comprehensive loss	(0)	(2)
Accumulated deficit	(157,676)	(155,979)
Total stockholders' equity	106,384	107,599
Total liabilities and stockholders' equity	$ 109,334	$ 110,469

About Eliem Therapeutics, Inc.

Eliem Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy, and other disorders of the peripheral and central nervous systems. Its lead drug candidate is ETX-123, a Kv7.2/3 potassium channel opener, which is in preclinical for the treatment of neuronal excitability disorders, such as epilepsy, pain, depression, and others; and ETX-155 for the treatment of major depressive disorder and focal onset seizures that is in Phase 2a clinical trial. The company was incorporated in 2018 and is headquartered in Redmond, Washington.

WEBSITE	https://eliemtx.com
INDUSTRY	Biotechnology
EMPLOYEES	30

Eliem Therapeutics, Inc. Frequently Asked Questions

What is the ticker symbol for Eliem Therapeutics, Inc.? What does ELYM stand for in stocks?

ELYM is the stock ticker symbol of Eliem Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Eliem Therapeutics, Inc. (ELYM)?

As of Fri May 17 2024, market cap of Eliem Therapeutics, Inc. is 239.71 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ELYM stock?

You can check ELYM's fair value in chart for subscribers.

What is the fair value of ELYM stock?

You can check ELYM's fair value in chart for subscribers. The fair value of Eliem Therapeutics, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Eliem Therapeutics, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ELYM so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Eliem Therapeutics, Inc. a good stock to buy?

The fair value guage provides a quick view whether ELYM is over valued or under valued. Whether Eliem Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact Eliem Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ELYM.

What is Eliem Therapeutics, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, ELYM's PE ratio (Price to Earnings) is -16.5 and Price to Sales (PS) ratio is 47.36. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ELYM PE ratio will change depending on the future growth rate expectations of investors.